Claim · claimSorter/cs-024

Ibogaine is the most promising psychedelic for treating opioid use disorder and PTSD in veterans

Education, not medical advice. Drafts and study material from an independent research library. Citations on this page were checked on Oct 13, 2026; claims in the body text and organizational sources are still under review. What was checked.

Ibogaine is the most promising psychedelic for treating opioid use disorder and PTSD in veterans

Partially Confirmed recorded as “Promising, Evidence Still Early” Food of the Gods

Small studies showing dramatic results: Noller et al. 2018 (n=14 OUD): 69% reduction in withdrawal symptoms. Stanford, Cherian et al. 2024 (Nature Medicine, n=30 veterans with traumatic brain injury, open-label with no control group): large reductions in PTSD, depression and disability ratings at one month. Texas allocated $50M for ibogaine research in 2025, Mississippi enacted an ibogaine research bill (HB 314) in March 2026. BUT: ibogaine has cardiac risks (QTc prolongation) that have caused deaths; no Phase 3 RCT has been completed; no FDA approval pathway established. Evidence is compelling enough to fund large trials; not strong enough to establish clinical efficacy.

Noller et al. (2018); Cherian et al., Nature Medicine (2024); cannabis magazine report (April 2026)